On October 6, 2022 Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, reported that Thomas Willemsen, President and CEO, Wilson W. Cheung, Chief Financial Officer, and Ivan D. Horak, M.D., Chief Medical Officer and Chief Scientific Officer, will participate in the 2nd Annual Needham Biotech Private Company 1×1 Forum being held virtually October 18-19 2022 (Press release, Tessa Therapeutics, OCT 6, 2022, View Source;1-forum/ [SID1234623201]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the conference, Mr. Willemsen, Mr. Cheung, and Dr. Horak will conduct one-on-one meetings with registered investors to discuss Tessa’s business strategy, recent corporate achievements, advancements with its autologous and allogeneic CAR-T programs, and anticipated developmental milestones.